Literature DB >> 9553100

Addressing the tertiary structure of human parathyroid hormone-(1-34).

M Pellegrini1, M Royo, M Rosenblatt, M Chorev, D F Mierke.   

Abstract

Parathyroid hormone (PTH) regulates mineral metabolism and bone turnover by activating specific receptors located on osteoblastic and renal tubular cells and is fully functional as the N-terminal 1-34 fragment, PTH-(1-34). Previously, a "U-shaped" conformation with N- and C-terminal helices brought in close proximity by a turn has been postulated. The general acceptance of this hypothesis, despite limited experimental evidence, has altered the direction of the design of PTH-analogs. Examining the structure of human PTH-(1-34) under conditions that encompass the different environments the hormone may experience in the approach to and interaction with the G-protein-coupled receptor (including benign aqueous and saline solutions and in the presence of dodecylphosphocholine), we observe no evidence for a U-shape conformation or any tertiary structure. Instead, the N- and C-terminal helical domains, which vary in length and stability depending on the conditions, are separated by a highly flexible region of undefined conformation. These observations are in complete accord with recent conformational studies of PTH-related protein analogs containing lactams (Mierke, D. F., Maretto, S., Schievano, E. , DeLuca, D., Bisello, A., Mammi, S., Rosenblatt, M., Peggion, E., and Chorev, M. (1997) Biochemistry 36, 10372-10383) or a model amphiphilic alpha-helix (Pellegrini, M., Bisello, A., Rosenblatt, M., Chorev, M., and Mierke, D. F. (1997) J. Med. Chem. 40, 3025-3031). Reliable structural data from different environmental conditions are absolutely requisite for the next step in the design of non-peptide PTH analogs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553100     DOI: 10.1074/jbc.273.17.10420

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Interaction of PTH and PTHrP with their receptors.

Authors:  T J Gardella; H Jüppner
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Architecture of recombination intermediates visualized by in-gel FRET of lambda integrase-Holliday junction-arm DNA complexes.

Authors:  Marta Radman-Livaja; Tapan Biswas; Dale Mierke; Arthur Landy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

3.  Mapping ligand-receptor interfaces: approaching the resolution limit of benzophenone-based photoaffinity scanning.

Authors:  Angela Wittelsberger; Dale F Mierke; Michael Rosenblatt
Journal:  Chem Biol Drug Des       Date:  2008-02-29       Impact factor: 2.817

4.  Recombinant production of TEV cleaved human parathyroid hormone.

Authors:  Christopher O Audu; Jared C Cochran; Maria Pellegrini; Dale F Mierke
Journal:  J Pept Sci       Date:  2013-06-23       Impact factor: 1.905

Review 5.  International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors.

Authors:  Thomas J Gardella; Jean-Pierre Vilardaga
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 6.  The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms.

Authors:  Arpád Dobolyi; Miklós Palkovits; Ted B Usdin
Journal:  Prog Neurobiol       Date:  2009-10-24       Impact factor: 11.685

7.  Structural basis for antibody discrimination between two hormones that recognize the parathyroid hormone receptor.

Authors:  William J McKinstry; Galina Polekhina; Hannelore Diefenbach-Jagger; Patricia W M Ho; Koh Sato; Etsuro Onuma; Matthew T Gillespie; T John Martin; Michael W Parker
Journal:  J Biol Chem       Date:  2009-04-04       Impact factor: 5.157

8.  Parathyroid hormone is a heparin/polyanion binding protein: binding energetics and structure modification.

Authors:  Tim J Kamerzell; Sangeeta B Joshi; Donald McClean; Lori Peplinskie; Karen Toney; Damon Papac; Meili Li; C Russell Middaugh
Journal:  Protein Sci       Date:  2007-06       Impact factor: 6.725

Review 9.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.